نتائج البحث

Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies.

• Authors : Gessner, Christian¹ (AUTHOR); Potthoff, Karin² (AUTHOR); Frost, Nikolaj³ (AUTHOR)

• Source: Oncology Research & Treatment. 2021, Vol. 44 Issue 3, p93-102. 10p.

تفاصيل العنوان

Hematopoietic Support With Moderately Myelosuppressive Chemotherapy Regimens: A Nursing Perspective.

• Authors : Moore, Kelley¹; Crom, Debbie

• Source: Clinical Journal of Oncology Nursing. Jun2006, Vol. 10 Issue 3, p383-388. 6p.

تفاصيل العنوان

Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy.

• Authors : Kleinman, M B; Wiley, E L; Guo, M

• Source: Bone Marrow Transplantation. 6/15/99, Vol. 23 Issue 12, p1297. 5p.

تفاصيل العنوان

Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study

• Authors : Stefan Fruehauf; Oliver J. Stötzer; Christine Rudolph

Subjects: 0301 basic medicine; Oncology; Male

• Source: Advances in Therapy

تفاصيل العنوان

Comparison of Efficacy and Safety of Lupin’s Pegfilgrastim with Neulastim® as an Adjunct to Chemotherapy in Patients with NonMyeloid Malignancies: A Randomised Phase III Clinical Study.

• Authors : JAIN, MINISH¹; DESAI, SHARAD²; NAGARKAR, RAJNISH³

• Source: Journal of Clinical & Diagnostic Research. Aug2022, Vol. 16 Issue 8, p1-7. 7p.

تفاصيل العنوان

Efficacy and safety of pegfilgrastim biosimilar MD‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III.

• Authors : Takano, Toshimi¹ (AUTHOR) ; Ito, Mitsuya² (AUTHOR); Kadoya, Takayuki³ (AUTHOR)

• Source: Cancer Medicine. Oct2023, Vol. 12 Issue 20, p20242-20250. 9p.

تفاصيل العنوان

Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.

• Authors : Mahtani, Reshma¹ (AUTHOR) ; Crawford, Jeffrey² (AUTHOR); Flannery, Sinéad M.³ (AUTHOR)

• Source: BMC Cancer. 5/27/2021, Vol. 21 Issue 1, p1-19. 19p.

تفاصيل العنوان

Prescription patterns of granulocyte colony–stimulating factors in patients with breast cancer: A real-world study.

• Authors : Hsu, Shu-Wei^1,2 (AUTHOR); Chiang, Shao-Chin^3,4 (AUTHOR); Hsu, Jason C.^5,6,7,8 (AUTHOR)

Subjects: *GRANULOCYTE-colony stimulating factor; *GRANULOCYTES; *CANCER patients

• Source: PLoS ONE. 7/17/2023, Vol. 18 Issue 7, p1-10. 10p.

تفاصيل العنوان

Real-World Use of Granulocyte-Colony Stimulating Factor in Patients with Breast Cancer from Alberta, Canada.

• Authors : Ding, Philip Q.^1,2 (AUTHOR); Newcomer, Brandt J.³ (AUTHOR); Cheung, Winson Y.^1,4 (AUTHOR)

• Source: Cancers. 12/15/2022, Vol. 14 Issue 24, p6197. 12p.

تفاصيل العنوان

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.

• Authors : Ferrarotto, Renata¹ (AUTHOR) ; Anderson, Ian² (AUTHOR); Medgyasszay, Balazs³ (AUTHOR)

• Source: Cancer Medicine. Sep2021, Vol. 10 Issue 17, p5748-5756. 9p.

تفاصيل العنوان